Daxor Accelerates Blood Volume Analysis Adoption with the Launch of ezBVA Lab Services
June 15, 2023 08:00 ET
|
Daxor Corporation
Daxor’s ezBVA Lab Designed to Drive Greater Prescriber Access and Utilization Across the United States Oak Ridge, TN, June 15, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global...
Daxor Corporation to Participate in the Maxim Group Virtual Healthcare Conference
June 12, 2023 08:00 ET
|
Daxor Corporation
Oak Ridge, TN, June 12, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced that Michael Feldschuh, CEO and President...
Daxor Corporation Announces Closing of $4.0 Million Underwritten Public Offering
May 25, 2023 15:37 ET
|
Daxor Corporation
Oak Ridge, TN, May 25, 2023 (GLOBE NEWSWIRE) -- DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the closing of...
Daxor Corporation Announces Pricing of $4.0 Million Underwritten Public Offering
May 22, 2023 08:30 ET
|
Daxor Corporation
Oak Ridge, TN, May 22, 2023 (GLOBE NEWSWIRE) -- DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the pricing of...
Daxor Corporation Announces Proposed Underwritten Public Offering
May 19, 2023 16:53 ET
|
Daxor Corporation
Oak Ridge, TN, May 19, 2023 (GLOBE NEWSWIRE) -- DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announces that it has...
New Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in Heart Failure Outcomes
May 18, 2023 08:00 ET
|
Daxor Corporation
Daxor’s BVA Technology Shown to Provide Unique and Individualized Data for Patient Management Oak Ridge, TN, May 18, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader...
New Studies Presented at the 43rd International Society for Heart and Lung Transplant Validate the Applicability of the BVA-100® Blood Test for Patients with Advanced Heart Failure
April 20, 2023 08:00 ET
|
Daxor Corporation
Study Demonstrates BVA Provides More Accurate Congestion Measurement in Challenging Patient Populations Oak Ridge, TN, April 20, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global...
Daxor Corporation to Exhibit at the MedAxiom Cardiovascular Transforum Conference Spring’23 to Advance Awareness and Further Adoption of Daxor’s Blood Volume Diagnostic (BVA-100®)
April 17, 2023 08:00 ET
|
Daxor Corporation
Expert Users to Present “Blood Volume Analysis – Breaking the Heart Failure Cycle” Oak Ridge, TN, April 17, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood...
Daxor Corporation to Exhibit at the 43rd International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions
April 13, 2023 08:00 ET
|
Daxor Corporation
Company to Showcase Three New Research Studies Utilizing Blood Volume Analysis Oak Ridge, TN, April 13, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume...
New Study Confirms Daxor’s BVA-100® Volume Metric Compared to CardioMEMS® Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients
March 23, 2023 08:30 ET
|
Daxor Corporation
Commonly Used Pressure Measure for Volume Assessment Discordant with Direct Measurement by BVA Oak Ridge, TN, March 23, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in...